PHARMAC responds on Herceptin assumptions and decisions.
作者信息
Metcalfe Scott, Evans Jackie
出版信息
N Z Med J. 2007 Aug 24;120(1260):U2692.
PMID:17726504
Abstract
摘要
相似文献
1
PHARMAC responds on Herceptin assumptions and decisions.
N Z Med J. 2007 Aug 24;120(1260):U2692.
2
PHARMAC and Herceptin for early-stage breast cancer in New Zealand: Herceptin or deception?
N Z Med J. 2006 Jun 2;119(1235):U2014.
3
PHARMAC's funding of 9 weeks Herceptin: many assumptions in a high-risk decision.
N Z Med J. 2007 Aug 10;120(1259):U2676.
4
5
Roche responds to the 'Herceptin or deception' article.
N Z Med J. 2006 Jul 7;119(1237):U2069; author reply U2069.
6
Patient demand and politics push Herceptin forward.
CMAJ. 2005 Aug 16;173(4):347-8. doi: 10.1503/cmaj.050883.
7
GlaxoSmithKline cancer drug threatens Herceptin market.
Nat Biotechnol. 2005 Dec;23(12):1453-4. doi: 10.1038/nbt1205-1453.
8
The hype over herceptin.
Nurs N Z. 2009 Mar;15(2):4-5.
9
Skipping for herceptin funds.
Nurs N Z. 2007 Nov;13(10):4.
10
Raising money for herceptin.
Nurs N Z. 2007 Mar;13(2):3.
引用本文的文献
1
Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses.
Per Med. 2009 Mar;6(2):193-215. doi: 10.2217/17410541.6.2.193.
Zotero 插件